Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 1:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 7,459 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced Solid Tumors
Interventions
IMC-1121B, 1121B
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus

NCT01781975
Conditions
Diabetes Mellitus, Type I, Diabetes Mellitus, Insulin-Dependent, 1, Type 1 Diabetes Mellitus, Insulin-Dependent Diabetes Mellitus 1, IDDM
Interventions
Imatinib Mesylate, Placebo (For imatinib mesylate)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Conditions
Multiple Sclerosis (MS)
Interventions
elezanumab, placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
30
States / cities
Phoenix, Arizona • Berkeley, California • Carlsbad, California + 24 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Intismeran autogene, Placebo
Biological · Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2038
U.S. locations
55
States / cities
Gilbert, Arizona • Tucson, Arizona • Fullerton, California + 43 more
Conditions
Adverse Effects in the Therapeutic Use of Other and Unspecified Agents Affecting Blood Constituents
Interventions
Massive Transfusion Group, Control Group
Other
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • Fort Sam Houston, Texas
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Obinutuzumab, Observation Activity, Venetoclax
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
65 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
857
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 555 more
Conditions
Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Olanzapine, Chemotherapy (cisplatin or cyclophosphamide and doxorubicin), Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant), Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
177
States / cities
Anchorage, Alaska • Burbank, California • Dublin, California + 109 more
Conditions
Hepatitis C, HIV Coinfection
Interventions
TDF with a boosted protease inhibitor, TAF with a boosted protease inhibitor, TAF with a boosted protease inhibitor and LDV/SOF
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions
MammaPrint
Device
Lead sponsor
Agendia
Industry
Eligibility
18 Years to 90 Years · Female only
Enrollment
820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
53
States / cities
Phoenix, Arizona • Burbank, California • Palm Springs, California + 47 more
Conditions
Dilated Cardiomyopathies, Idiopathic, Heart Failure, Systolic, Ventricular Remodeling, Electrical Remodeling
Interventions
Ivabradine, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Columbus, Ohio
Conditions
Congenital Heart Disease in Children
Interventions
Ductal Arterial Stent, Systemic-to-Pulmonary Artery Shunt
Device · Procedure
Lead sponsor
Carelon Research
Other
Eligibility
1 Day to 30 Days
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 20 more
Conditions
Glaucoma
Interventions
standard of care, education
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Hemophilia B with Inhibitor, Hemophilia B
Interventions
SerpinPC
Drug
Lead sponsor
ApcinteX Ltd
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Aurora, Colorado • Tampa, Florida • Greenville, North Carolina
Conditions
Stage I Colon Cancer AJCC v8, Stage I Rectal Cancer AJCC v8, Stage II Colon Cancer AJCC v8, Stage II Rectal Cancer AJCC v8, Stage IIA Colon Cancer AJCC v8, Stage IIA Rectal Cancer AJCC v8, Stage IIB Colon Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8, Stage IIC Rectal Cancer AJCC v8, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Colon Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
Interventions
Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
716
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 438 more
Conditions
Sickle Cell Disease
Interventions
VIT-2763 120 mg, VIT-2763 360 mg, VIT-2763 240 mg, Placebo BID, Placebo TID
Drug
Lead sponsor
Vifor (International) Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 5 more
Conditions
Type 1 Diabetes
Interventions
Pump suspension algorithm
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
3 Years to 14 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Stanford, California • Aurora, Colorado
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions
Pegcetacoplan (APL-2), Placebo
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 7 more
Conditions
Deep Venous Thrombosis
Interventions
Enoxaparin
Drug
Lead sponsor
Yale University
Other
Eligibility
Up to 17 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 18 more
Conditions
Multiple Sclerosis
Interventions
ELND002, Placebo
Drug
Lead sponsor
Elan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
17
States / cities
Berkeley, California • Fresno, California • Newport Beach, California + 14 more
Conditions
C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
Interventions
LNP023
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2036
U.S. locations
5
States / cities
Aurora, Colorado • Lawrenceville, Georgia • Iowa City, Iowa + 2 more
Conditions
Chronic Kidney Disease, Autosomal Dominant Polycystic Kidney Disease
Interventions
Tolvaptan (OPC-41061), Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
82
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 73 more
Conditions
Epilepsies, Partial
Interventions
Placebo, 2400mg SPN-804, 1200mg SPN-804
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
23
States / cities
Huntsville, Alabama • Northport, Alabama • Phoenix, Arizona + 20 more
Conditions
Influenza
Interventions
13 valent pneumococcal conjugate vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 59 Years
Enrollment
1,116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
41
States / cities
Chandler, Arizona • Rolling Hills Estates, California • Aurora, Colorado + 29 more
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
Interventions
Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration, Relatlimab
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
495
States / cities
Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 374 more